Caruncho Héctor J, Rivera-Baltanás Tania
Departamento de Biología Celular. Grupo de Investigación BIOFARMA, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, España.
Rev Neurol. 2010 Apr 16;50(8):470-6.
The delay in the actions of antidepressants as well as the percentage of patients that do not respond to antidepressant treatment, give rise to a keen interest in the development of biomarkers of therapeutic efficacy in depression, but it is also of importance to work towards the development of biomarkers of vulnerability, diagnosis and prognosis of this disorder.
To analyze what is known of the main genetic, molecular and biochemical biomarkers of depression already validated, and to discuss the present and future of this research field.
Among the most repeatedly validated biomarkers of depression are the decrease in serotonin transporter binding in platelets and lymphocytes, hypercortisolemia, hypocholesteremia, decrease in brain-derived neurotrophic factor, decrease in CREB phosphorylation, and an increase in interleukin 6.
Some biomarkers related to the pharmacogenetics of antidepressants are already a reality, now the next step will be to develop biomarkers of pathophysiological processes that correlate with important clinical aspects of depression.
抗抑郁药起效延迟以及对抗抑郁治疗无反应的患者比例，引发了人们对抑郁症治疗疗效生物标志物开发的浓厚兴趣，但致力于该疾病易感性、诊断和预后生物标志物的开发也很重要。
分析已得到验证的抑郁症主要遗传、分子和生化生物标志物的相关情况，并探讨该研究领域的现状与未来。
在反复得到验证的抑郁症生物标志物中，包括血小板和淋巴细胞中5-羟色胺转运体结合减少、高皮质醇血症、低胆固醇血症、脑源性神经营养因子减少、CREB磷酸化减少以及白细胞介素6增加。
一些与抗抑郁药药物遗传学相关的生物标志物已经成为现实，下一步将是开发与抑郁症重要临床方面相关的病理生理过程生物标志物。
